Torley Helen 4
4 · HALOZYME THERAPEUTICS, INC. · Filed May 13, 2026
Research Summary
AI-generated summary of this filing
Halozyme (HALO) CEO Helen Torley Exercises Options, Sells Shares
What Happened
Helen Torley, President and CEO of Halozyme Therapeutics (HALO), exercised a total of 50,000 stock options (code M) at a $12.07 exercise price (cost ≈ $603,500) and sold the 50,000 resulting common shares in multiple open‑market transactions on May 11–13, 2026. The shares were sold for total gross proceeds of approximately $3,433,874 (sales prices ranged roughly from $64.03 to $73.77 per share). These exercises and sales were executed under a written Rule 10b5‑1 trading plan.
Key Details
- Transaction dates: May 11–13, 2026.
- Options exercised: 50,000 shares (20,000 on 5/11, 20,000 on 5/12, 10,000 on 5/13) at $12.07 each (total exercise cost ≈ $603,500).
- Shares sold: 50,000 shares across multiple trades (total proceeds ≈ $3,433,874).
- Net cash before taxes/fees (proceeds minus exercise cost): roughly $2.83M.
- Price range: sales reported between about $64.03 and $73.77 per share; grouped weighted averages and exact per‑trade prices are provided in the filing footnotes.
- Footnotes: sales were made pursuant to a 10b5‑1 plan adopted March 21, 2025; the exercised options had a ten‑year term expiring February 2027. (See footnotes F1 and F13.)
- Shares owned after the transactions: not specified in the provided filing excerpt.
- Filing timeliness: Report filed May 13, 2026 for transactions through May 11–13, 2026; filing appears timely (no late‑filing flag shown).
Context
- Code M indicates option exercise; because the newly acquired shares were sold immediately, this functions like a cashless exercise (exercise + simultaneous open‑market sales).
- The sales were executed under a pre‑arranged 10b5‑1 plan, which is commonly used to automate insider trades and reduce questions about trading on nonpublic information.
- These transactions are factual disclosures of insider activity; they do not by themselves indicate the insider's future view of the company.
Insider Transaction Report
Form 4
Torley Helen
DirectorPRESIDENT AND CEO
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-05-11$12.07/sh+20,000$241,400→ 787,780 total - Sale
Common Stock
[F1][F2]2026-05-11$64.63/sh−9,725$628,536→ 778,055 total - Sale
Common Stock
[F1][F3]2026-05-11$65.46/sh−3,575$234,012→ 774,480 total - Sale
Common Stock
[F1][F4]2026-05-11$66.33/sh−6,700$444,391→ 767,780 total - Exercise/Conversion
Common Stock
[F1]2026-05-12$12.07/sh+20,000$241,400→ 787,780 total - Sale
Common Stock
[F1]2026-05-12$67.85/sh−100$6,785→ 787,680 total - Sale
Common Stock
[F1][F5]2026-05-12$70.29/sh−1,398$98,261→ 786,282 total - Sale
Common Stock
[F1][F6]2026-05-12$71.37/sh−9,802$699,569→ 776,480 total - Sale
Common Stock
[F1][F7]2026-05-12$72.15/sh−5,900$425,673→ 770,580 total - Sale
Common Stock
[F1][F8]2026-05-12$73.12/sh−2,800$204,739→ 767,780 total - Exercise/Conversion
Common Stock
2026-05-13$12.07/sh+10,000$120,700→ 777,780 total - Sale
Common Stock
[F1][F9]2026-05-13$68.10/sh−2,100$143,014→ 775,680 total - Sale
Common Stock
[F1][F10]2026-05-13$68.88/sh−3,350$230,748→ 772,330 total - Sale
Common Stock
[F1][F11]2026-05-13$69.79/sh−3,950$275,659→ 768,380 total - Sale
Common Stock
[F1][F12]2026-05-13$70.81/sh−600$42,487→ 767,780 total - Exercise/Conversion
Option to Purchase Common Stock
[F13]2026-05-11$12.07/sh−20,000$241,400→ 81,923 totalExercise: $12.07Exp: 2027-02-22→ Common Stock (20,000 underlying) - Exercise/Conversion
Option to Purchase Common Stock
[F13]2026-05-12$12.07/sh−20,000$241,400→ 61,923 totalExercise: $12.07Exp: 2027-02-22→ Common Stock (20,000 underlying) - Exercise/Conversion
Option to Purchase Common Stock
[F13]2026-05-13$12.07/sh−10,000$120,700→ 51,923 totalExercise: $12.07Exp: 2027-02-22→ Common Stock (10,000 underlying)
Footnotes (13)
- [F1]The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027.
- [F10]Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.450 to $69.440. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F11]Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.450 to $70.050. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F12]Represents a weighted average sales price per share. The shares were sold at prices ranging from $70.480 to $71.220. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F13]Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017.
- [F2]Represents a weighted average sales price per share. The shares were sold at prices ranging from $64.030 to $65.010. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]Represents a weighted average sales price per share. The shares were sold at prices ranging from $65.030 to $66.010. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F4]Represents a weighted average sales price per share. The shares were sold at prices ranging from $66.040 to $66.720. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F5]Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.740 to $70.700. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F6]Represents a weighted average sales price per share. The shares were sold at prices ranging from $70.800 to $71.795 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F7]Represents a weighted average sales price per share. The shares were sold at prices ranging from $71.805 to $72.780. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F8]Represents a weighted average sales price per share. The shares were sold at prices ranging from $72.810 to $73.770. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F9]Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.450 to $68.440. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Signature
/s/ James R. Oehler, Attorney-in-Fact|2026-05-13